- Home
- GLSI
as of 11-28-2025 12:12pm EST
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | STAFFORD |
| Market Cap: | 108.8M | IPO Year: | 2020 |
| Target Price: | $39.00 | AVG Volume (30 days): | 85.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.78 - $15.47 | Next Earning Date: | 11-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered GLSI Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Greenwich LifeSciences Inc. (GLSI)
CEO and CFO
Avg Cost/Share
$8.37
Shares
4,600
Total Value
$38,502.00
Owned After
5,588,102
SEC Form 4
CEO and CFO
Avg Cost/Share
$8.43
Shares
10,600
Total Value
$89,358.00
Owned After
5,588,102
SEC Form 4
CEO and CFO
Avg Cost/Share
$9.26
Shares
2,300
Total Value
$21,298.00
Owned After
5,588,102
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Patel Snehal | GLSI | CEO and CFO | Nov 25, 2025 | Buy | $8.37 | 4,600 | $38,502.00 | 5,588,102 | |
| Patel Snehal | GLSI | CEO and CFO | Nov 7, 2025 | Buy | $8.43 | 10,600 | $89,358.00 | 5,588,102 | |
| Patel Snehal | GLSI | CEO and CFO | Oct 31, 2025 | Buy | $9.26 | 2,300 | $21,298.00 | 5,588,102 |
Compare GLSI vs Leading Stocks
See how GLSI stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GLSI Greenwich LifeSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.